Two pharmaceutical giants are competing for investor attention in 2026, but only one appears to offer the stronger near-term growth case.
AbbVie Inc (NYSE: ABBV) operates as a broad biopharmaceutical company with diversified exposure across immunology, oncology, and aesthetics, serving hospitals, specialty pharmacies, and government agencies.
Novo Nordisk A/S (NYSE: NVO) takes a narrower approach, focusing almost exclusively on chronic disease management through its industry-leading diabetes and obesity drug portfolio.
AbbVie posted revenue of $61.2 billion in FY 2025, representing growth of approximately 8.7% compared to the prior year, while net income for the same period came in at $4.2 billion.
The company generated $17.8 billion in free cash flow during FY 2025, though its balance sheet carries a debt-to-equity ratio of negative 21x, meaning total liabilities exceed shareholder equity.
AbbVie’s distribution network is heavily concentrated among three major wholesale partners: McKesson Corp (NYSE: MCK), Cardinal Health Inc (NYSE: CAH), and Cencora Inc (NYSE: COR).
Novo Nordisk reported FY 2025 revenue of $48.2 billion, with net income of nearly $16 billion and an impressive net margin of 33%, well ahead of AbbVie’s 7% margin for the same period.
Despite its superior profitability, Novo Nordisk trades at lower valuation multiples, with a forward price-to-earnings ratio of 13.8x compared to AbbVie’s 16.1x, and a price-to-sales ratio of 3.9x versus 7.2x.
Novo Nordisk faces growing pressure from a federal pricing agreement on its GLP-1 drugs, the emergence of generic competitors, and advances by Eli Lilly and Co (NYSE: LLY) in developing next-generation weight-loss treatments.
The once-daily Wegovy pill launch in the United States has been a clear success, and an injectable patent on Ozempic and Wegovy runs through 2032, providing meaningful competitive insulation for now.
Wall Street currently projects Novo Nordisk’s sales will decline roughly 3% in fiscal 2026 and net income will contract approximately 4% as pricing pressure erodes margins, before a recovery driven by new products.
AbbVie’s two newer immunology drugs, Skyrizi and Rinvoq, combined for approximately 42% of total company sales in 2025, demonstrating that the post-Humira transition is gaining real momentum.
The company is also acquiring Apogee Therapeutics and has a pipeline that analysts believe could yield blockbuster treatments for schizophrenia, Parkinson’s disease, Alzheimer’s-related psychosis, and certain solid tumors.
AbbVie is expected to deliver dramatic income growth in the current year, with net income projected to rise from $4.2 billion to $14.6 billion while sales grow to $67.2 billion.
Given that growth trajectory, the slightly higher valuation premiums on AbbVie’s forward price-to-earnings and price-to-sales ratios appear justified for investors willing to wait while Novo Nordisk navigates a more competitive market landscape.
